North America Artificial Blood Substitutes Market, By Product Type (Perflurocarbon (PFCs) and Hemoglobin-Based Oxygen Carries (HBOCs)), Source (Human Blood, Animal Blood, Microorganism Based Recombinant HB, Synthetic Polymers and Stem Cells), Application (Cardiovascular Diseases, Malignant Neoplasma, Injuries, Neonatal Conditions, Organ Transplant and Maternal Condition), End User (Hospital & Clinics, Blood Banks and Others), Country (U.S., Mexico) Industry Trends and Forecast To 2028.
Market Analysis and Insights: North America Artificial Blood Substitutes Market
The artificial blood substitutes market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses that the market is growing with a CAGR of 26.4% in the forecast period of 2021 to 2028 and is expected to reach USD 17,803.70 thousand by 2028. Limited availability of fresh blood and its short life span coupled with increasing demand for blood transfusion and increased funding for development of blood substitutes acts as driver for the artificial blood substitutes market growth.
Artificial blood substitutes are also known as oxygen therapeutics or haemoglobin-based oxygen carriers. It is used to mimic the function of biological blood and to offer a substitute to blood transfusion. Artificial blood are used as a solution to replace transfusion of banked red blood cells and are designed to overcome the limitations such as shortage of blood sonor, high risk contamination, requirement of cross matching. The allogenic blood transfusions has multiple risks and can cause infectious transmission, transfusion reactions, transfusion related acute lung injury, delayed postoperative wound healing, immunomodulation and potential risk of cancer recurrence. It offers the promise of new and important life-saving medical treatments.
Artificial blood are produced from sources such as animal blood, human blood, microorganisms recombinant Hb, stem cells and others. Artificial blood also offers several advantages over the human blood as it belongs to universal blood group and can be given to the patients regardless of their blood type. Also artificial blood substitutes don’t produce any immulogical reactions. Also, artificial blood substitute eliminates the risk of infectious diseases or contamination during transfusion and offers extended shelf life in comparision to the human blood as it can be stored for 3 years at room temperature or more while the human blood shelf life is short for 42 days. Artificial blood can be used for emergency situations and can be stored easily also is the perfect option for the patients who doesn’t accept blood from donors due to their religious beliefs.
Limited availability of fresh blood and its short life span coupled with increasing demand for blood transfusion and increased funding for development of blood substitutes are the key factors driving the North America artificial blood substitutes market. However, the high cost production of artificial blood as well as stringent rules laid down by governmental bodies for approval of blood substitute products may hamper the growth of the artificial blood substitutes market. Also, rising awareness regarding the advantages offered by artificial blood and rising demand for artificial blood coupled with insufficient number of blood donor and growing number of research and development on artificial blood will create huge opportunities for the North America artificial blood substitutes market. The inavailability of artificial blood products, extended clinical trials and side effects associated with artificial blood will create a huge challenge for the North America artificial blood substitutes market.
The artificial blood substitutes market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the artificial blood substitutes market scenario contact Data Bridge Market Research for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.
Artificial blood substitutes Market Scope and Market Size
The artificial blood substitutes market is segmented on the based on the product type, source, application and end user. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
- On the basis of product type, the North America artificial blood substitutes market is segmented into perflurocarbon (PFCs) and hemoglobin-based oxygen carries (HBOCs). Perflurocarbon (PFCs) is further segmented into perftoran. Hemoglobin-based oxygen carries (HBOCs) is further segmented into oxyglobin and hemopure. In 2021, the hemoglobin-based oxygen carries (HBOCs) segment is expected to dominate the artificial blood substitutes market due to rising demand for blood substitutes which eliminates the blood typing and to overcome the shortage of human blood.
- On the basis of source, the North America artificial blood substitutes market is segmented into human blood, animal blood, microorganism based recombinant HB, synthetic polymers and stem cells. In 2021, the animal blood segment is expected to dominate the artificial blood substitutes market due to availability of ample amount of source to produce artificial blood.
- On the basis of application, the North America artificial blood substitutes market is segmented into cardiovascular diseases, malignant neoplasma, injuries, neonatal conditions, organ transplant and maternal condition. In 2021, the injuries segment is expected to dominate the artificial blood substitutes market due to rising incidence of injuries, road accidents and others and high demand for artificial blood to treat them.
- On the basis of end user, the North America artificial blood substitutes market is segmented into hospital & clinics, blood banks and others. In 2021, the hospital & clinics segment is expected to dominate the artificial blood substitutes market due to rising number of patients with various illness and growing need for blood.
Artificial blood substitutes Market Country Level Analysis
The artificial blood substitutes market is analyzed and market size information is provided by the country, product type, source, application and end user as referenced above.
The countries covered in the artificial blood substitutes market report are the U.S., Mexico.
Product type segment in U.S. country is expected to grow with the highest growth rate in the forecast period of 2021 to 2028 because of increase in demand for blood transfusion with rising number of patients. The product type segment in Mexico is dominating market owing to limited availability of human blood to treat rising number of patients.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of North America brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Growing Strategic Activities by Major Market Players to Enhance the Awareness for Artificial blood substitutes is boosting the Market Growth of Artificial blood substitutes market.
The artificial blood substitutes market also provides you with detailed market analysis for every country growth in particular market. Additionally, it provides the detail information regarding the market players’ strategy and their geographical presence. The data is available for historic period 2010 to 2019.
Competitive Landscape and Artificial blood substitutes Market Share Analysis
Artificial blood substitutes market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the company’s focus related to artificial blood substitutes market.
The major companies which are dealing in the artificial blood substitutes are HEMARINA, Hemoglobin Oxygen Therapeutics LLC, KaloCyte, Inc., LLC “Visusmed”, European Medicines Agency, OPK Biotech LLC, NuvOx Pharma, Prolong Pharmaceuticals, LLC, Boston Therapeutics, Inc., Aurum Biosciences, OXYVITA Inc, NanoBlood LLC among other domestic players. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.
Many expansion and funding are also initiated by the companies’ worldwide which are also accelerating the artificial blood substitutes market.
For instance,
- In November 2020, Hemarina published a scientific report for anti-inflammatory and antibacterial property of M 101, an oxygen transporter for the treatment of periodontitis. This study has validated the quality of M 101 molecolue, which is derived from haemoglobin of the marine lugworm.
- In June 2020, KaloCyte, Inc. received a USD 300k funding from University System of Maryland (USM) Momentum Fund for developing ErythroMer, a synthetic, bio-inspired red blood substitute. This funding has helped the company in developing the ErythroMer at much faster pace.
- In May 2020, KaloCyte, Inc. awarded by the National Institutes of Health (NIH) a USD 373,000 Small Buisness Innovation Resaerch (SBIR) Phase I grant. This grant helped the company in advancing KaloCyte product to preclinical safety and efficacy testing in anticipation of human trails.
Collaboration, business expansion, award and recognition, joint ventures and other strategies by the market player is enhancing the company footprints in the artificial blood substitutes market which also provides the benefit for organization’s profit growth.
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF NORTH AMERICA ARTIFICIAL BLOOD SUBSTITUTES MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.7 MULTIVARIATE MODELLING
2.8 PRODUCT TYPE LIFELINE CURVE
2.9 DBMR MARKET POSITION GRID
2.1 MARKET APPLICATION COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
5 PATENT ANALYSIS OF NORTH AMERICA ARTIFICIAL BLOOD SUBSTITUTES MARKET
5.1 DBMR ANALYSIS
5.2 COUNTRY-LEVEL ANALYSIS
5.3 YEARWISE ANALYSIS
6 NORTH AMERICA ARTIFICIAL BLOOD SUBSTITUTES MARKET: PIPELINE ANALYSIS
7 MARKET OVERVIEW
7.1 DRIVERS
7.1.1 INCREASE IN DEMAND FOR BLOOD TRANSFUSION
7.1.2 INCREASED FUNDING FOR PRODUCT DEVELOPMENT
7.1.3 RISE IN BLOOD-RELATED DISORDERS AND TRAUMA CASES
7.1.4 LIMITED AVAILABILITY OF FRESH BLOOD AND SMALL STORAGE PERIODS OF FRESH BLOOD
7.2 RESTRAINTS
7.2.1 STRINGENT REGULATORY APPROVAL PROCESS
7.2.2 HIGH-COST PRODUCTION OF ARTIFICIAL BLOOD SUBSTITUTE
7.2.3 UNAWARENESS ABOUT THE ARTIFICIAL BLOOD SUBSTITUTES
7.3 OPPORTUNITIES
7.3.1 INCREASE IN AWARENESS REGARDING THE ADVANTAGES OF ARTIFICIAL BLOOD OVER HUMAN BLOOD
7.3.2 RISE IN DEMAND FOR BLOOD SUBSTITUTES AND INSUFFICIENT NUMBER OF BLOOD DONORS
7.3.3 RISE IN NUMBER OF RESEARCH & DEVELOPMENTS ON ARTIFICIAL BLOOD
7.3.4 AMPLE AMOUNT OF SOURCES FOR PRODUCTION OF ARTIFICIAL BLOOD SUBSTITUTE
7.4 CHALLENGES
7.4.1 INSTABILITY OF ARTIFICIAL BLOOD PRODUCT
7.4.2 EXTENDED CLINICAL TRAILS
7.4.3 SIDE EFFECTS OF ARTIFICIAL BLOOD SUBSTITUTES
8 IMPACT OF COVID-19 ON THE NORTH AMERICA ARTIFICIAL BLOOD SUBSTITUTES MARKET
8.1 AFTERMATH OF COVID-19
8.2 IMPACT ON SUPPLY AND DEMAND
8.3 THE INCREASING DEMAND FOR BLOOD TRANSFUSION IS LEADING THE ARTIFICIAL BLOOD SUBSTITUTES MARKET.
8.4 CONCLUSION
9 NORTH AMERICA ARTIFICIAL BLOOD SUBSTITUTES MARKET, BY PRODUCT TYPE
9.1 OVERVIEW
9.2 HEMOGLOBIN-BASED OXYGEN CARRIES (HBOCS)
9.2.1 OXYGLOBIN
9.2.2 HEMOPURE
9.3 PERFLUOROCARBON (PFCS)
9.3.1 PERFTORAN
9.3.2 OTHERS
10 NORTH AMERICA ARTIFICIAL BLOOD SUBSTITUTES MARKET, BY SOURCE
10.1 OVERVIEW
10.2 ANIMAL BLOOD
10.3 HUMAN BLOOD
10.4 MICROORGANISM BASED RECOMBINANT HB
10.5 STEM CELLS
10.6 SYNTHETIC POLYMERS
11 NORTH AMERICA ARTIFICIAL BLOOD SUBSTITUTES MARKET, BY APPLICATION
11.1 OVERVIEW
11.2 INJURIES
11.3 CARDIOVASCULAR DISEASES
11.4 ORGAN TRANSPLANT
11.5 MATERNAL CONDITION
11.6 MALIGNANT NEOPLASMA
11.7 NEONATAL CONDITIONS
12 NORTH AMERICA ARTIFICIAL BLOOD SUBSTITUTES MARKET, BY END USER
12.1 OVERVIEW
12.2 HOSPITAL AND CLINICS
12.3 BLOOD BANKS
12.4 OTHERS
13 NORTH AMERICA ARTIFICIAL BLOOD SUBSTITUTES MARKET, BY REGION
13.1 NORTH AMERICA
13.1.1 U.S.
13.1.2 MEXICO
14 NORTH AMERICA ARTIFICIAL BLOOD SUBSTITUTES MARKET: COMPANY LANDSCAPE
14.1 COMPANY SHARE ANALYSIS: NORTH AMERICA
15 SWOT
16 COMPANY PROFILE
16.1 KALOCYTE, INC.
16.1.1 COMPANY SNAPSHOT
16.1.2 COMPANY SAHRE ANALYSIS
16.1.3 PRODUCT PORTFOLIO
16.1.4 RECENT DEVELOPMENTS
16.2 HEMARINA
16.2.1 COMPANY SNAPSHOT
16.2.2 COMPANY SHARE ANALYSIS
16.2.3 PRODUCT PORTFOLIO
16.2.4 RECENT DEVELOPMENTS
16.3 HEMOGLOBIN OXYGEN THERAPEUTICS LLC
16.3.1 COMPANY SNAPSHOT
16.3.2 COMPANY SHARE ANALYSIS
16.3.3 PRODUCT PORTFOLIO
16.3.4 RECENT DEVELOPMENTS
16.4 LLC “VISUSMED”
16.4.1 COMPANY SNAPSHOT
16.4.2 COMPANY SHARE ANALYSIS
16.4.3 PRODUCT PORTFOLIO
16.4.4 RECENT DEVELOPMENT
16.5 EUROPEAN MEDICINES AGENCY
16.5.1 COMPANY SNAPSHOT
16.5.2 REVENUE ANALYSIS
16.5.3 COMPANY SHARE ANALYSIS
16.5.4 PRODUCT PORTFOLIO
16.5.5 RECENT DEVELOPMENT
16.6 AURUM BIOSCIENCES
16.6.1 COMPANY SNAPSHOT
16.6.2 PRODUCT PORTFOLIO
16.6.3 RECENT DEVELOPMENTS
16.7 BOSTON THERAPEUTICS, INC.
16.7.1 COMPANY SNAPSHOT
16.7.2 REVENUE ANALYSIS
16.7.3 PRODUCT PORTFOLIO
16.7.4 RECENT DEVELOPMENT
16.8 NANOBLOOD LLC
16.8.1 COMPANY SNAPSHOT
16.8.2 PRODUCT PORTFOLIO
16.8.3 RECENT DEVELOPMENT
16.9 NUVOX PHARMA
16.9.1 COMPANY SNAPSHOT
16.9.2 PRODUCT PORTFOLIO
16.9.3 RECENT DEVELOPMENTS
16.1 OPK BIOTECH LLC
16.10.1 COMPANY SNAPSHOT
16.10.2 PRODUCT PORTFOLIO
16.10.3 RECENT DEVELOPMENT
16.11 OXYVITA INC
16.11.1 COMPANY SNAPSHOT
16.11.2 PRODUCT PORTFOLIO
16.11.3 RECENT DEVELOPMENT
16.12 PROLONG PHARMACEUTICALS, LLC
16.12.1 COMPANY SNAPSHOT
16.12.2 PRODUCT PORTFOLIO
16.12.3 RECENT DEVELOPMENT
17 QUESTIONNAIRE
18 RELATED REPORTS
List of Table
TABLE 1 NORTH AMERICA ARTIFICIAL BLOOD SUBSTITUTES MARKET, PRODUCT TYPE, 2019-2028 (USD THOUSAND)
TABLE 2 NORTH AMERICA HEMOGLOBIN-BASED OXYGEN CARRIES (HBOCS) IN ARTIFICIAL BLOOD SUBSTITUTES MARKET, BY REGION, 2019-2028 (USD THOUSAND)
TABLE 3 NORTH AMERICA HEMOGLOBIN-BASED OXYGEN CARRIERS (HBOCS) IN ARTIFICIAL BLOOD SUBSTITUTES MARKET, BY PRODUCT TYPE, 2019-2028 (USD THOUSAND)
TABLE 4 NORTH AMERICA PERFLUOROCARBON (PFCS) IN ARTIFICIAL BLOOD SUBSTITUTES MARKET, BY REGION, 2019-2028 (USD THOUSAND)
TABLE 5 NORTH AMERICA PERFLUOROCARBON (PFCS) IN ARTIFICIAL BLOOD SUBSTITUTES MARKET, BY PRODUCT TYPE, 2019-2028 (USD THOUSAND)
TABLE 6 NORTH AMERICA ARTIFICIAL BLOOD SUBSTITUTES MARKET, BY SOURCE, 2019-2028 (USD THOUSAND)
TABLE 7 NORTH AMERICA ANIMAL BLOOD IN ARTIFICIAL BLOOD SUBSTITUTES MARKET, BY REGION, 2019-2028 (USD THOUSAND)
TABLE 8 NORTH AMERICA HUMAN BLOOD IN ARTIFICIAL BLOOD SUBSTITUTES MARKET, BY REGION, 2019-2028 (USD THOUSAND)
TABLE 9 NORTH AMERICA MICROORGANISM BASED RECOMBINANT HB IN ARTIFICIAL BLOOD SUBSTITUTES MARKET, BY REGION, 2019-2028 (USD THOUSAND)
TABLE 10 NORTH AMERICA STEM CELLS IN ARTIFICIAL BLOOD SUBSTITUTES MARKET, BY REGION, 2019-2028 (USD THOUSAND)
TABLE 11 NORTH AMERICA SYNTHETIC POLYMERS IN ARTIFICIAL BLOOD SUBSTITUTES MARKET, BY REGION, 2019-2028 (USD THOUSAND)
TABLE 12 NORTH AMERICA ARTIFICIAL BLOOD SUBSTITUTES MARKET, BY APPLICATION, 2019-2028 (USD THOUSAND)
TABLE 13 NORTH AMERICA INJURIES IN ARTIFICIAL BLOOD SUBSTITUTES MARKET, BY REGION, 2019-2028 (USD THOUSAND)
TABLE 14 NORTH AMERICA CARDIOVASCULAR DISEASES IN ARTIFICIAL BLOOD SUBSTITUTES MARKET, BY REGION, 2019-2028 (USD THOUSAND)
TABLE 15 NORTH AMERICA ORGAN TRANSPLANT IN ARTIFICIAL BLOOD SUBSTITUTES MARKET, BY REGION, 2019-2028 (USD THOUSAND)
TABLE 16 NORTH AMERICA MATERNAL CONDITION IN ARTIFICIAL BLOOD SUBSTITUTES MARKET, BY REGION, 2019-2028 (USD THOUSAND)
TABLE 17 NORTH AMERICA MALIGNANT NEOPLASMA IN ARTIFICIAL BLOOD SUBSTITUTES MARKET, BY REGION, 2019-2028 (USD THOUSAND)
TABLE 18 NORTH AMERICA NEONATAL CONDITIONS IN ARTIFICIAL BLOOD SUBSTITUTES MARKET, BY REGION, 2019-2028 (USD THOUSAND)
TABLE 19 NORTH AMERICA ARTIFICIAL BLOOD SUBSTITUTES MARKET, BY END USER, 2019-2028 (USD THOUSAND)
TABLE 20 NORTH AMERICA HOSPITALS AND CLINICS IN ARTIFICIAL BLOOD SUBSTITUTES MARKET, BY REGION, 2019-2028 (USD THOUSAND)
TABLE 21 NORTH AMERICA BLOOD BANKS IN ARTIFICIAL BLOOD SUBSTITUTES MARKET, BY REGION, 2019-2028 (USD THOUSAND)
TABLE 22 NORTH AMERICA OTHERS IN ARTIFICIAL BLOOD SUBSTITUTES MARKET, BY REGION, 2019-2028 (USD THOUSAND)
TABLE 23 NORTH AMERICA ARTIFICIAL BLOOD SUBSTITUTES MARKET, BY COUNTRY, 2019-2028 (USD THOUSAND)
TABLE 24 NORTH AMERICA ARTIFICIAL BLOOD SUBSTITUTES MARKET, BY PRODUCT TYPE, 2019-2028 (USD THOUSAND)
TABLE 25 NORTH AMERICA HEMOGLOBIN-BASED OXYGEN CARRIES (HBOCS) IN ARTIFICIAL BLOOD SUBSTITUTES MARKET, BY PRODUCT TYPE, 2019-2028 (USD THOUSAND)
TABLE 26 NORTH AMERICA PERFLUOROCARBON (PFCS) IN ARTIFICIAL BLOOD SUBSTITUTES MARKET, BY PRODUCT TYPE, 2019-2028 (USD THOUSAND)
TABLE 27 NORTH AMERICA ARTIFICIAL BLOOD SUBSTITUTES MARKET, BY SOURCE, 2019-2028 (USD THOUSAND)
TABLE 28 NORTH AMERICA ARTIFICIAL BLOOD SUBSTITUTES MARKET, BY APPLICATION, 2019-2028 (USD THOUSAND)
TABLE 29 NORTH AMERICA ARTIFICIAL BLOOD SUBSTITUTES MARKET, BY END USER, 2019-2028 (USD THOUSAND)
TABLE 30 U.S. ARTIFICIAL BLOOD SUBSTITUTES MARKET, BY PRODUCT TYPE, 2019-2028 (USD THOUSAND)
TABLE 31 U.S. HEMOGLOBIN-BASED OXYGEN CARRIES (HBOCS) IN ARTIFICIAL BLOOD SUBSTITUTES MARKET, BY PRODUCT TYPE, 2019-2028 (USD THOUSAND)
TABLE 32 U.S. PERFLUOROCARBON (PFCS) IN ARTIFICIAL BLOOD SUBSTITUTES MARKET, BY PRODUCT TYPE, 2019-2028 (USD THOUSAND)
TABLE 33 U.S. ARTIFICIAL BLOOD SUBSTITUTES MARKET, BY SOURCE, 2019-2028 (USD THOUSAND)
TABLE 34 U.S. ARTIFICIAL BLOOD SUBSTITUTES MARKET, BY APPLICATION, 2019-2028 (USD THOUSAND)
TABLE 35 U.S. ARTIFICIAL BLOOD SUBSTITUTES MARKET, BY END USER, 2019-2028 (USD THOUSAND)
TABLE 36 MEXICO ARTIFICIAL BLOOD SUBSTITUTES MARKET, BY PRODUCT TYPE, 2019-2028 (USD THOUSAND)
TABLE 37 MEXICO HEMOGLOBIN-BASED OXYGEN CARRIES (HBOCS) IN ARTIFICIAL BLOOD SUBSTITUTES MARKET, BY PRODUCT TYPE, 2019-2028 (USD THOUSAND)
TABLE 38 MEXICO PERFLUOROCARBON (PFCS) IN ARTIFICIAL BLOOD SUBSTITUTES MARKET, BY PRODUCT TYPE, 2019-2028 (USD THOUSAND)
TABLE 39 MEXICO ARTIFICIAL BLOOD SUBSTITUTES MARKET, BY SOURCE, 2019-2028 (USD THOUSAND)
TABLE 40 MEXICO ARTIFICIAL BLOOD SUBSTITUTES MARKET, BY APPLICATION, 2019-2028 (USD THOUSAND)
TABLE 41 MEXICO ARTIFICIAL BLOOD SUBSTITUTES MARKET, BY END USER, 2019-2028 (USD THOUSAND)
List of Figure
FIGURE 1 NORTH AMERICA ARTIFICIAL BLOOD SUBSTITUTES MARKET: SEGMENTATION
FIGURE 2 NORTH AMERICA ARTIFICIAL BLOOD SUBSTITUTES MARKET: DATA TRIANGULATION
FIGURE 3 NORTH AMERICA ARTIFICIAL BLOOD SUBSTITUTES MARKET: DROC ANALYSIS
FIGURE 4 NORTH AMERICA ARTIFICIAL BLOOD SUBSTITUTES MARKET: NORTH AMERICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 NORTH AMERICA ARTIFICIAL BLOOD SUBSTITUTES MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 NORTH AMERICA ARTIFICIAL BLOOD SUBSTITUTES MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 NORTH AMERICA ARTIFICIAL BLOOD SUBSTITUTES MARKET: DBMR MARKET POSITION GRID
FIGURE 8 NORTH AMERICA ARTIFICIAL BLOOD SUBSTITUTES MARKET: MARKET APPLICATION COVERAGE GRID
FIGURE 9 NORTH AMERICA ARTIFICIAL BLOOD SUBSTITUTES MARKET: DBMR VENDOR SHARE ANALYSIS
FIGURE 10 NORTH AMERICA ARTIFICIAL BLOOD SUBSTITUTES MARKET: SEGMENTATION
FIGURE 11 INCREASED DEMAND FOR BLOOD TRANSFUSION IS EXPECTED TO DRIVE THE NORTH AMERICA ARTIFICIAL BLOOD SUBSTITUTES MARKET IN THE FORECAST PERIOD OF 2021 TO 2028
FIGURE 12 HAEMOGLOBIN-BASED OXYGEN CARRIERS (HBOCS) SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA ARTIFICIAL BLOOD SUBSTITUTES MARKET IN 2021 & 2028
FIGURE 13 PATENT REGISTERED FOR ARTIFICIAL BLOOD SUBSTITUTES, BY COUNTRY
FIGURE 14 PATENT REGISTERED YEAR (2017 - 2021)
FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF NORTH AMERICA ARTIFICIAL BLOOD SUBSTITUTES MARKET
FIGURE 16 NORTH AMERICA ARTIFICIAL BLOOD SUBSTITUTES MARKET, BY PRODUCT TYPE, 2020
FIGURE 17 NORTH AMERICA ARTIFICIAL BLOOD SUBSTITUTES MARKET, BY SOURCE, 2020
FIGURE 18 NORTH AMERICA ARTIFICIAL BLOOD SUBSTITUTES MARKET, BY APPLICATION, 2020
FIGURE 19 NORTH AMERICA ARTIFICIAL BLOOD SUBSTITUTES MARKET, BY END USER, 2020
FIGURE 20 NORTH AMERICA ARTIFICIAL BLOOD SUBSTITUTES MARKET: SNAPSHOT (2020)
FIGURE 21 NORTH AMERICA ARTIFICIAL BLOOD SUBSTITUTES MARKET: BY COUNTRY (2020)
FIGURE 22 NORTH AMERICA ARTIFICIAL BLOOD SUBSTITUTES MARKET: BY COUNTRY (2021 & 2028)
FIGURE 23 NORTH AMERICA ARTIFICIAL BLOOD SUBSTITUTES MARKET: BY COUNTRY (2020 & 2028)
FIGURE 24 NORTH AMERICA ARTIFICIAL BLOOD SUBSTITUTES MARKET: BY PRODUCT TYPE (2021-2028)
FIGURE 25 NORTH AMERICA ARTIFICIAL BLOOD SUBSTITUTES MARKET: COMPANY SHARE 2020 (%)
Research Methodology
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
Customization Available
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.